

Final version

Thank you Chair.

Medicines Patent Pool (MPP) have a comment regarding the “additional benefits” provided for in Article 12(8), including non-exclusive licensing and technology transfer, which are important areas of implementation of the pandemic agreement.

The “additional benefits” provided for in Article 12(8), including non-exclusive licensing and technology transfer, are central to MPP’s mandate and reflect our long-standing collaboration with WHO and Member States.

A concrete example is the mRNA Technology Transfer Programme, co-led by WHO and MPP with participation of 15 countries. Initially established to address inequitable access to COVID-19 vaccines, the Programme now provides a platform to strengthen regional manufacturing capacity and future pandemic preparedness.

Significant progress has been achieved: establishment of Technology Transfer Center, global network of 16 manufacturers, sharing of an mRNA technology platform, and creation of manufacturing capacity.

As the Programme enters its second phase, the network is well placed to contribute to future pandemic preparedness and response, with potential collective output exceeding 1.9 billion doses by 2030. It has also evolved into a broader innovation platform, with regional research and development consortia advancing work on priority pathogens and next-generation mRNA applications, including vaccines and potential therapeutics, thereby helping to sustain capacity between outbreaks and to strengthen regional innovation ecosystems.

More broadly, MPP’s non-exclusive licensing model has expanded access to innovative health products in more than 140 low- and middle-income countries and is increasingly supporting the diversification of global manufacturing. Taken together, these two mechanisms illustrate how the additional benefits envisaged under Article 12(8) of the Pandemic Agreement can be operationalized in practice.

We would therefore respectfully propose that the WHO–MPP mRNA Technology Transfer Programme and public health-oriented licensing through MPP be taken into consideration within the PABS benefit-sharing system as a practical means of translating commitments into timely and tangible outcomes.